Stock market information for Alkermes plc (ALKS)
- Alkermes plc is a equity in the USA market.
- The price is 32.0 USD currently with a change of -0.03 USD (-0.00%) from the previous close.
- The latest open price was 31.84 USD and the intraday volume is 1,650,208.
- The intraday high is 32.27 USD and the intraday low is 31.78 USD.
- The latest trade time is Thursday, February 19, 14:35:00 PST.
Background
Alkermes plc is a global biopharmaceutical company specializing in the development, manufacture, and commercialization of innovative medicines for complex psychiatric and neurological disorders. Founded in 1987 by Michael Wall, the company is headquartered in Dublin, Ireland, with research and development facilities in Waltham, Massachusetts, and a manufacturing plant in Wilmington, Ohio. Alkermes focuses on addressing unmet medical needs in areas such as addiction, schizophrenia, bipolar disorder, and sleep disorders.
Key Strategic Focus
Alkermes' strategic focus centers on developing treatments for serious and chronic diseases, particularly within the central nervous system (CNS). The company's core objectives include:
- Innovative Drug Delivery Technologies: Advancing proprietary drug delivery systems to improve therapeutic outcomes.
- Specialized Therapeutic Areas: Concentrating on addiction, schizophrenia, bipolar disorder, and sleep disorders.
- Pipeline Expansion: Developing a robust pipeline of clinical and preclinical candidates targeting neurological and psychiatric conditions.
Alkermes employs technologies such as extended-release formulations and novel receptor agonists to enhance treatment efficacy and patient compliance.
Financials and Funding
As of the second quarter of 2025, Alkermes reported revenues of $390.7 million, marking a 14% year-over-year increase. The company maintains a strong financial position with over $1 billion in cash reserves and no debt. In November 2025, Alkermes completed the acquisition of Avadel Pharmaceuticals plc for $2.37 billion, aiming to expand its presence in the sleep medicine market.
Pipeline Development
Alkermes' pipeline includes several promising candidates:
- Alixorexton (ALKS 2680): An oral orexin 2 receptor agonist in Phase 2 development for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
- Sodium Oxybate Extended-Release Oral Suspension: A Phase 3 study for idiopathic hypersomnia is ongoing.
- Lybalvi (Olanzapine and Samidorphan): A combination therapy for schizophrenia and bipolar I disorder, currently in Phase 3 trials for pediatric indications.
Technological Platform and Innovation
Alkermes distinguishes itself through:
- Proprietary Drug Delivery Systems: Innovative technologies that enhance the pharmacokinetics and patient adherence of treatments.
- Scientific Methodologies: Utilizing advanced receptor agonist designs and formulations to address complex CNS disorders.
Leadership Team
The executive team comprises:
- Richard F. Pops: Chief Executive Officer, leading the company since 1987.
- Craig Hopkinson, M.D.: Executive Vice President, Research & Development and Chief Medical Officer, overseeing R&D initiatives.
- James M. Frates: Chief Financial Officer, managing financial operations.
- Madeline Coffin: Senior Vice President, Human Resources, responsible for talent management.
- Kathy Biberstein: Executive Vice President, Chief Administrative & Legal Officer, Chief Compliance & Risk Officer, Board Secretary, handling legal and compliance matters.
Competitor Profile
- Market Insights and Dynamics: The CNS disorder treatment market is competitive, with companies like Johnson & Johnson, Otsuka Pharmaceutical, and Merck holding significant market shares.
- Competitor Analysis: Key competitors include:
- Johnson & Johnson: Offers products such as Risperdal Consta and Invega Sustenna.
- Otsuka Pharmaceutical: Markets Abilify Maintena.
- Merck: Provides various CNS treatments.
- Strategic Collaborations and Partnerships: Alkermes collaborates with companies like Johnson & Johnson and AstraZeneca to co-market products, enhancing its market reach.
Operational Insights
Alkermes' focus on CNS disorders positions it in a growing market, with its proprietary drug delivery technologies offering a competitive edge. The company's strategic partnerships further strengthen its market position.
Strategic Opportunities and Future Directions
Alkermes aims to:
- Expand Pipeline: Advance treatments for sleep disorders and other CNS conditions.
- Leverage Acquisitions: Integrate Avadel Pharmaceuticals to enhance sleep medicine offerings.
- Strengthen Collaborations: Pursue additional partnerships to broaden product reach and development capabilities.
Contact Information
- Website: www.alkermes.com
- LinkedIn: Alkermes
- Headquarters: Dublin, Ireland
